IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
22 hedge funds and large institutions have $4.78M invested in IO Biotech in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 4 closing their positions.
33% more capital invested
Capital invested by funds: $3.59M → $4.78M (+$1.19M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 21 → 22 (+1)
4.11% less ownership
Funds ownership: 15.02% → 10.91% (-4.1%)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$376K |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$336K |
| 3 |
Citigroup
New York
|
+$81.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$33.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$27.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$932K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$463K |
| 3 |
Renaissance Technologies
New York
|
-$252K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$121K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$104K |
IOBT Hedge Fund Activity: Q4 2025 in Review
22 of the 8,256 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q4 2025, worth a combined $4.78M — up 33% from $3.59M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IOBT positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Beacon Pointe Advisors, opening a new position worth an estimated $376K. The largest seller was Millennium Management, cutting an estimated $932K.
- 22 institutional investors held IO Biotech (IOBT) as of Q4 2025, up from 21 in Q3 2025.
- Funds reported $4.78M of IO Biotech stock for Q4 2025, up 33% quarter-over-quarter.
- 5 funds opened new IO Biotech positions in Q4 2025 and 4 closed out, a net change of +1 holder.
- The largest IO Biotech buyer in Q4 2025 was Beacon Pointe Advisors, an estimated $376K added.
- The largest IO Biotech seller in Q4 2025 was Millennium Management, an estimated $932K sold.
Based on aggregated 13F filings for Q4 2025.